Altimmune Inc
NASDAQ:ALT
Products
Altimmune Says FDA Issued A Clinical Hold On Company's Investigational New Drug Application For Adcovid
Published: 12/23/2020 21:20 GMT
Altimmune Inc (ALT) - Altimmune Provides an Update on Its Investigational New Drug Application for a Phase 1 Adcovid™ Clinical Trial.
Altimmune Inc - FDA Issued a Clinical Hold on Company's Investigational New Drug Application for Adcovid.
Altimmune Inc - Agency Requested Certain Protocol Modifications and Submission of Additional Chemistry, Manufacturing and Controls Data.
Altimmune - at This Time, Does Not Anticipate a Significant Impact on Overall Clinical Development Timeline As Co Has Agreed to Each of FDA's Requests.
Altimmune Inc - Has Responded to Agency's Clinical Hold Letter Received on December 22.
Altimmune Inc - FDA Issued a Clinical Hold on Company's Investigational New Drug Application for Adcovid.
Altimmune Inc - Agency Requested Certain Protocol Modifications and Submission of Additional Chemistry, Manufacturing and Controls Data.
Altimmune - at This Time, Does Not Anticipate a Significant Impact on Overall Clinical Development Timeline As Co Has Agreed to Each of FDA's Requests.
Altimmune Inc - Has Responded to Agency's Clinical Hold Letter Received on December 22.